Early Efficacy Seen With Tislelizumab/Nab-Paclitaxel in High-Risk NMIBC
The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.
Neoadjuvant Tislelizumab/Nab-Paclitaxel Shows Interim Benefit in MIBC
Tislelizumab plus nab-paclitaxel as neoadjuvant treatment demonstrated benefit with a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.
Antibody-Drug Conjugate Targets' Expression Levels Analyzed in Bladder Cancers
Both TROP-2 and Nectin-4 were shown to be highly expressed in urothelial cancer and variant histology bladder cancer, but not in patients with neuroendocrine histology.
IS-002 is Well-Tolerated in Patients Undergoing Robotic Prostatectomy
IS-002 was shown to be safe, well-tolerated, and allow for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy, according to findings from a phase 1 study.
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Neoadjuvant Axitinib May Enable Partial Nephrectomy in Subgroup of Patients with RCC
Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.
Added Darolutamide Does Not Increase Toxicity With ADT/Docetaxel in mHSPC
Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Benefit of Co-Treatment Chemotherapy and Vitamin C in Cisplatin-Ineligible MIBC
Chemotherapy plus intravenous vitamin C shows benefit in cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.
Positive Harm-Benefit Data Reported in Black Patients With Prostate Cancer
Data supporting prostate-specific antigen screening shows harm-benefit tradeoff to be more favorable with complementary approaches to quantifying overdiagnosis.
Relugolix Shows Tolerable Safety in Advanced Prostate Cancer
The safety profile of relugolix in patients with advanced prostate cancer has been demonstrated in the phase 3 HERO clinical trial.
Upfront Avelumab Maintenance Prolongs Overall Survival in Urothelial Carcinoma
Long-term follow-up results from the JAVELIN Bladder 100 study further support the standard-of-care role of avelumab as frontline maintenance in patients with urothelial carcinoma.
Prior Local Treatment Does Not Impact Survival Benefit of Enzalutamide/ADT in mHSPC
Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
Darolutamide Continues to Show Strong Efficacy in nmCRPC After 3 Years, Regardless of Prior Therapy
Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.
Long-Term DFS Benefit Shown With Nivolumab in Urothelial Carcinoma
In patients with high-risk, muscle-invasive urothelial carcinoma treated in the adjuvant nivolumab lead to clinically meaningful improvements in disease-free survival compared with placebo.
PARP and AR Inhibitor Regimen Improve Efficacy in mCRPC
Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.
Long-Term Survival Benefit Shown With Enzalutamide Plus ADT in mHSPC
Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.
18F-rhPSMA-7.3 Increases Upstaging of Disease in Recurrent Prostate Cancer
Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.
Association Between irAEs and Prolonged Survival With Pembrolizumab in Metastatic Urothelial Carcinoma
Immune-related adverse effects may show significantly longer progression-free survival and overall survival in patients with metastatic urothelial carcinoma who are receiving pembrolizumab.
Potential for Overcoming Olaparib Resistance in Prostate Cancer
Alan Lombard, PhD, shared insight on mechanisms of resistance to PARP inhibition with olaparib and explained how this resistance may be overcome.
Durable Responses Seen in Low-Grade Upper Tract Urothelial Carcinoma After UGN-101 Induction
Durable responses in patients with low-grade upper tract urothelial carcinoma were seen with the mitomycin- containing reverse thermal gel UGN-101.
DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
A ‘More Active Role’ is Needed From Urologist in Reporting Smoking Assessment, Cessation in Clinical Trials
Future studies on genitourinary cancer may be limited as many currently lack data on how smoking impacts outcomes in this patient population.
Wellness Modality May Improve QoL and Immune Responses in Patients with Prostate Cancer
Phase 2 research highlights a wellness modality that may improve outcomes in men with prostate cancer.
Disease Recurrence Not Significantly Delayed With Panvac Plus BCG in Advanced NMIBC
n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.
Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.
Aveluamab With BCG Induction Shows Early Safety/Tolerability in BCG-Unresponsive NMIBC
Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Olaparib Combined With Pembrolizumab Signals Antitumor Activity in mCRPC
An update from KEYNOTE-365 trial shows the promising efficacy of olaparib in combination with pembrolizumab for patients with post-docetaxel metastatic castration-resistant prostate cancer.
Regardless of Prior Antiandrogen Therapy in mHSPC, Enzalutamide/ADT Maintains Efficacy
Regardless of prior antiandrogen therapy and its pretreatment duration, enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer.
2 Clarke Drive Cranbury, NJ 08512